Formulate And Evaluate A Zonisamide-Loaded Nanoemulsion For Intranasal Administration Bypassing The Blood-Brain Barrier For The Treatment Of Neurological Disorders

Zonisamide is an antiepileptic drug with limited brain availability when administered through conventional routes due to the restrictive nature of the blood-brain barrier (BBB). This study aims to develop and evaluate a nanoemulsion-based formulation of Zonisamide for intranasal delivery to enhance its direct transport to the brain. Nanoemulsions, due to their small droplet size and high surface area, offer improved drug solubility, stability, and permeation across biological membranes. The formulation was optimized using suitable oils, surfactants, and co-surfactants to ensure maximum drug loading, stability, and nasal mucosal compatibility. Various physicochemical parameters such as particle size, zeta potential, viscosity, and pH were assessed, along with in-vitro drug release and ex-vivo permeation studies through nasal mucosa. The developed formulation demonstrated promising characteristics for brain targeting via the intranasal route, potentially improving therapeutic outcomes in the management of neurological disorders while reducing systemic side effects. This approach offers a non-invasive and efficient strategy for delivering Zonisamide directly to the brain.